Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Icon CFO Nigel Bernard John Clerkin Sells $303K of Stock
Nigel Bernard John Clerkin, CFO, sold 1,466 shares of Icon PLC at $204.91 to $208.00 a share (average $206.61) in 4 transactions, worth $303K in total on Nov 2, 2026. Shares held after the trade: 7,193 (-5.0%).
Corcept Therapeutics reported a significant increase in net income to $126.8 million for the third quarter of 2026, compared to $19.7 million in the prior year, driven by a 64% increase in product revenue. The company maintained a strong balance sheet with over $1 billion in total assets and continued its stock repurchase program, though it recorded a net loss in the first quarter of the year.
Douglas Emmett reported Q3 2026 financial results, highlighting positive office absorption for the fourth consecutive quarter and a significant increase in office occupancy to 76.7%. Despite a net loss of $9 million, the company noted that its Net Operating Income has recovered to 2019 levels, though performance remains pressured by higher interest expenses.
Avery Dennison reported net sales of $2.33 billion for the third quarter of 2026, a 5.2% increase compared to the prior year. Net income for the nine months ended September 30, 2026, rose to $541.9 million, up from $521.6 million in 2025, driven by higher volume and productivity measures. The company identified significant risks including global economic conditions, raw material costs, and geopolitical uncertainty in the Middle East and Ukraine.
For the nine months ended September 30, 2026, Expro Ltd reported total revenue of $1.20 billion, a slight decrease from $1.22 billion in the prior year period. The company swung to a net loss of $4.2 million compared to a net income of $45.9 million in 2025, primarily driven by higher operating costs and a significant increase in merger and integration expenses.
USANA Health Sciences reported third quarter 2026 net sales of $206 million and a net loss of $5.6 million. While Core Nutritional active customers declined year-over-year, the company saw an 18% sequential increase in Hiya active monthly subscribers and generated $36 million in year-to-date free cash flow.
Term
Q3 2026
“As we continue our transformation to an omnichannel health and wellness company, our third quarter results were mixed, with meaningful improvement in some areas and results that fell short of our expectations in others.”
Kevin Guest, Chairman and Chief Executive Officer
“In Core Nutritional, rebuilding our active customer base is our top priority and our single largest growth lever.”
Corebridge Financial reported its third quarter 2026 results, highlighting a pending merger transaction with Equitable Holdings, Inc. The company maintains a large accelerated filer status with 438,475,911 shares of common stock outstanding as of October 30, 2026.
Safehold Inc. reported third quarter 2026 financial results, highlighted by revenue of $118.7 million and net income of $28.8 million. The company closed $38 million in new ground lease originations and noted that its estimated unrealized capital appreciation increased to $9.9 billion.
Term
Q3 2026
“We were pleased to convert additional multifamily ground leases in the third quarter at attractive yields and low GLTVs. While the recent rise in rates has added incremental volatility to transaction markets, we’re encouraged by the engagement we’re seeing with our customers, and are well-positioned with ample liquidity, no significant near-term maturities and an 18-year liability structure to capitalize on opportunities.”
Jay Sugarman, Chairman and Chief Executive Officer
Varonis Systems reported third quarter 2026 total revenues of $189.5 million, a 17% increase year-over-year, driven by significant growth in SaaS revenues which reached $185.1 million. The company noted it will not provide forward-looking guidance or hold an earnings call due to its pending acquisition by Proofpoint, a Thoma Bravo portfolio company.
National Bank Holdings Corp. (NBHC) has released an updated investor presentation for Q3 2026. The company intends to use this deck for upcoming meetings with investors, analysts, and other stakeholders to discuss its strategic objectives and financial trends.
Arista Networks reported record Q3 2026 financial results with revenue of $3.66 billion, representing 58.5% year-over-year growth. The company achieved record profitability with non-GAAP diluted EPS of $1.20 and provided strong Q4 guidance reflecting continued momentum in AI networking infrastructure.
Term
Q3 2026
“Arista registered another momentous quarter with the highest year-over-year revenue growth since our IPO and record profitability, surpassing even my high expectations. This strong momentum across customer sectors highlights our increased relevance for the generative and agentic AI era.”
Jayshree Ullal, Chairperson and CEO of Arista Networks
“This quarter brought a true trifecta for our company, setting new record highs in revenue growth, net income, and EPS. I’m incredibly proud of the Arista team for their hard work in driving such outstanding performance for our shareholders.”
Neostellar Capital Corp. reported its Q3 2026 financial results, showing a Net Asset Value (NAV) of $12.64 per share and total net assets of approximately $334.7 million. The company highlighted its formalized partnership with Magnetar and its investment portfolio of 34 companies, including significant positions in Whoop and OpenAI (via ARK Type One).
Term
Q3 2026
“During the third quarter, we formalized our partnership with Magnetar through Neostellar Advisors, expanding our resources for sourcing and due diligence and giving us greater flexibility to evaluate and structure investments.”
Mark Klein, Chairman and Chief Executive Officer
“We continue to see significant opportunity across the computing and data infrastructure supporting broader AI adoption, reflected in our investments in OpenAI, ClickHouse, TensorWave and CoreWeave.”
Phoenix Education Partners reported fiscal year 2026 net revenue of $1,017.0 million and net income of $88.9 million. The company also announced the appointment of Michael Weston, a Principal at Apollo Global Management, to its Board of Directors as a Class II director.
Term
FY2026
“As workforce needs evolve, the value of higher education increasingly lies in the knowledge and skills students develop and can apply in a changing workplace. We’re focused on providing that value through programs that deliver career-relevant skills, expanding offerings aligned with in-demand fields, and strengthening our relationships with employers to better understand and meet their workforce needs. With strong student retention and continued investment in the student experience, we remain focused on providing working adults with a relevant, high-quality education that meets their evolving needs.”
Chris Lynne, Chief Executive Officer of Phoenix Education Partners and President of the University of Phoenix
Alamar Biosciences reported Q3 2026 revenue of $33.5 million, a 68% year-over-year increase driven by strong demand for its NULISA platform and consumables. The company raised its full-year 2026 revenue guidance to a range of $121-$123 million and announced the retirement of President Tod White effective December 31, 2026.
Term
Q3 2026
“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time. Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”
Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences
“Tod has been an outstanding partner and leader during a pivotal period for Alamar. He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.”
Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company
Joby Aviation Insider Paul Cahill Sciarra Sells $311K of Stock
Paul Cahill Sciarra sold 62,500 shares of Joby Aviation, Inc. at $4.97 a share, worth $311K in total on Nov 2, 2026. Shares held after the trade: 55,578,057 (-0.1%).
Automatic Data Processing Corporate VP Michael A. Bonarti Sells $2.25M of Stock
Michael A. Bonarti, Corporate VP, sold 7,487 shares of Automatic Data Processing Inc at $300.00 a share, worth $2.25M in total on Nov 2, 2026. Shares held after the trade: 81,849 (-8.4%).
Marqeta reported Q3 2026 financial results with Total Processing Volume (TPV) growing 29% year-over-year to $126 billion. The company achieved its third consecutive quarter of GAAP profitability with net income of $115 million, aided by a $107 million non-cash income tax benefit.
Term
Q3 2026
“Our third quarter results demonstrate the durable, differentiated business Marqeta is building, as well as our focus on enhancing the platform that customers trust to build and scale their payment programs. TPV surpassed a $500 billion annualized run rate for the first time, Adjusted EBITDA margin set a new high-water mark, and we delivered our third consecutive quarter of GAAP profitability.”
Astera Labs reported record third-quarter 2026 revenue of $584.9 million, representing 154% year-over-year growth driven by high-volume production of its Scorpio fabric switches. The company achieved a GAAP net income of $182.9 million ($0.99 per diluted share) and expanded its product portfolio with the introduction of the Aries 7 PCIe 7 signal conditioning line and the Orion rack-scale reference architecture.
Term
Q3 2026
“Astera Labs delivered outstanding Q3 2026 results, with record quarterly revenue of $584.9 million, up 49% sequentially and up 154% year-over-year, with broad-based growth led by Scorpio, which ramped to high-volume production and became our largest product family by revenue.”
Automatic Data Processing Insider Carlos A. Rodriguez Sells $3.39M of Stock
Carlos A. Rodriguez sold 11,305 shares of Automatic Data Processing Inc at $300.02 to $300.06 a share (average $300.05) in 5 transactions, worth $3.39M in total on Nov 2, 2026. Shares held after the trade: 22,873 (-13.1%).
QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% decrease year-over-year primarily due to lower sales in China and a softer respiratory season. The company also announced a major cost transformation and restructuring program expected to deliver over $80 million in annual savings by 2027, involving a shift to two focused business units: Core Diagnostics and Point of Care Diagnostics.
Term
Q3 2026
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base. While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”
Brian J. Blaser, President and Chief Executive Officer
BlueLinx reported fiscal third quarter 2026 net sales of $813 million, an 8.5% increase year-over-year, driven by growth in both specialty and structural products. Despite the sales growth, the company recorded a net loss of $0.6 million due to an unusual inventory provision related to a strategic brand change, though Adjusted EBITDA rose 42% to $31.7 million.
Term
3 months
“Our strategy and our investments in growth initiatives, operational excellence, and process improvements are helping us successfully navigate a challenging environment and drive long-term value creation.”
Shyam Reddy, President and Chief Executive Officer
“Strong operational execution and effective working capital management contributed to our strong cash flow during the third quarter. Our balance sheet and liquidity remain strong, which give us a great deal of flexibility to execute on our strategic initiatives.”
Kelly Wall, Senior Vice President, Chief Financial Officer and Treasurer
Enhanced Group Inc. has filed a Certificate of Amendment to its Charter to effect a 1-for-10 reverse stock split of its Class A and Class B common stock. Additionally, the company entered into amendments to Transaction Support Agreements with its CEO and controlling shareholders to extend lock-up restrictions, eliminating a scheduled six-month partial release in favor of a full twelve-month lock-up period.
Nisource EVP & CFO Shawn Anderson Sells $292K of Stock
Shawn Anderson, EVP & CFO, sold 6,500 shares of Nisource Inc. at $45.00 a share, worth $292K in total on Oct 30, 2026. Shares held after the trade: 160,080 (-3.9%).
Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, a 64% increase year-over-year, driven by strong growth in Korlym and the rapid uptake of Lifyorli in ovarian cancer. Net income rose significantly to $126.8 million, or $1.01 per diluted share, while the company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.
Term
Q3 2026
“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business. Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”
Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer
“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome. Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”
Bill Guyer, PharmD, Corcept’s Chief Development Officer
For the nine months ended September 30, 2026, AES Corp reported total assets of $56.05 billion and a significant increase in retained earnings to $1.85 billion compared to $641 million at year-end 2025. The company maintained a strong liquidity position with $1.97 billion in cash and cash equivalents while managing a total debt load of approximately $33.26 billion.
American Express Group Pres., GMNS Anna Marrs Sells $14.7M of Stock
Anna Marrs, Group Pres., GMNS, sold 44,910 shares of American Express Co at $326.63 to $327.77 a share (average $327.20) in 3 transactions, worth $14.7M in total on Nov 2, 2026. Shares held after the trade: 20,509 (-39.6%).
HNI Corporation reported net sales of $1,592.9 million for the third quarter of 2026, a significant increase from $683.8 million in the prior year period. Despite the revenue growth, nine-month net income attributable to the corporation slightly decreased to $102.3 million compared to $103.4 million in 2025, impacted by higher interest expenses and restructuring costs.
Tarsus Pharmaceuticals reported a significant net loss of $693.9 million for the nine months ended September 30, 2026, primarily driven by $632.2 million in acquired in-process research and development expenses from the acquisitions of iRenix and Alkeus. Despite the net loss, total revenues grew to $530.5 million, up from $299.7 million in the prior year, fueled by strong product sales.
Mercury General Corp reported a net loss of $13.7 million for the third quarter of 2026, primarily driven by $261.9 million in net realized investment losses. Despite the quarterly loss, the company maintained a net income of $440.2 million for the first nine months of 2026, supported by a 10.7% year-over-year increase in net premiums earned.
Contineum Therapeutics reported third-quarter 2026 financial results, highlighting a net loss of $18.7 million and a cash position of $244.5 million. The company noted that its current capital resources are sufficient to fund operations through mid-2029, providing runway past the estimated completion of its Phase 2 PROPEL-IPF clinical trial. Research and development expenses increased 45% year-over-year to $16.0 million, primarily driven by the PIPE-791 program.
“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients. We believe the LPAR1 class can be the ideal backbone for combination treatments. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.”
Carmine Stengone, CEO, Contineum Therapeutics
“We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.”